Empery Asset Management, LP
CIK
1469336
Location
NEW YORK, NY
Portfolio Value
Micro
$1,112,233
Diversification
Highly concentrated
Filing Date
Global Rank
#6,590
/ 6,687
▼ 18
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+21.2%
Period ended 3 years ago
Filed Nov 14, 2022 · 3y
4 quarters · since Dec 2021
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+186.5%
SPY
+76.3%
Annualised alpha
+21.2%
Max drawdown
−60.4%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
2 positions · as of Sep 30, 2022 · Δ vs Jun 30, 2022Top Position
56.0%
−44.0 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
5,073
Highly concentrated−4,927
Portfolio Trend
4 quarters · across all stocks
Sector Breakdown
As of Sep 30, 2022| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,112,233 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | −619,518 | 308,466 | $623,101 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| MDNAF | Medicenna Therapeutics Corp. | 589,316 | $489,132 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
2 positions ·
$1,112,233 total
· as of Sep 30, 2022
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| SLS |
SELLAS Life Sciences Group, Inc.
Healthcare
|
Reduced | 308,466 | $623,101 | 56.02% | |
| MDNAF |
Medicenna Therapeutics Corp.
Healthcare
|
NEW | 589,316 | $489,132 | 43.98% |